JP MORGAN/CALL/ELI LILLY & CO/710/0.01/17.01.25 | Market Closed - Börse Stuttgart 09:46:07 14/06/2024 BST | ||
| 2.01 EUR | +8.06% |
|
| Current month | +34.00% | ||
| 1 month | +82.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 2.01 | +8.06% |
| 13/06/24 | 1.86 | -1.06% |
| 12/06/24 | 1.88 | -8.29% |
| 11/06/24 | 2.05 | +15.82% |
| 10/06/24 | 1.77 | +8.59% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 09:46 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK26DV |
| ISIN | DE000JK26DV0 |
| Date issued | 08/02/2024 |
| Strike | 710 $ |
| Maturity | 17/01/2025 (215 Days) |
| Parity | 100 : 1 |
| Emission price | 0.89 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.05 € |
|---|---|
| Lowest since issue | 0.96 € |
| Spread | 0.01 € |
| Spread % | 0.51% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Warrants
- Warrant